An eight-week, randomized, double blind, two parallel groups, study to assess clinical response of duloxetine 60 mg and 120 per day in patients hospitalized for severe depression

Trial Profile

An eight-week, randomized, double blind, two parallel groups, study to assess clinical response of duloxetine 60 mg and 120 per day in patients hospitalized for severe depression

Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Jul 2012

At a glance

  • Drugs Duloxetine (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 04 Jul 2012 Planned number of patients changed from 324 to 410 as reported by European Clinical Trials Database.
    • 21 Sep 2010 Results published in the Journal of Clinical Psychiatry.
    • 12 Sep 2009 Results presented at the 22nd Annual Congress of the European College of Neuropsychopharmacology (ECNP 2009).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top